聚乙二醇干扰素治疗慢性丙肝患者对于机体细胞免疫功能的影响

Effects of pegylated interferon on cellular immune function in patients with chronic hepatitis C

目的探讨聚乙二醇干扰素治疗慢性丙肝的临床疗效及对机体细胞免疫功能的影响效果。方法选取本院2013年6月~2016年10月收治的92例慢性丙肝患者作为研究对象,经单双数字法（入院就诊顺序）随机均分为研究组和对照组,每组46例。对照组在常规治疗基础上加用重组人干扰素α-2b,研究组在常规治疗基础上加用聚乙二醇干扰素α-2a。结果治疗后研究组RVR、EVR、ETVR、SVR几率（分别为52.17%、71.74%、76.09%、54.35%）均显著高于对照组（分别为34.78%、50.00%、58.70%、39.13%）,对比差异有统计学意义（P〈0.05）。治疗前2组慢性丙肝患者各项细胞免疫功能指标对比差异无统计学意义;治疗后研究组CD3＋、CD4＋、CD4＋/CD8＋等细胞免疫功能指标均较治疗前显著提高,而CD8~＋检测结果则较治疗前显著下降（P〈0.05）;对照组细胞免疫功能指标较治疗前差异无统计学意义,2组治疗后细胞免疫功能指标对比差异有统计学意义（P〈0.05）。结论在常规治疗基础上加用聚乙二醇干扰素有利于提高慢性丙肝患者机体病毒学应答效果及细胞免疫功能。

Objective To investigate the clinical effect of pegylated interferon（ IFN） on chronic hepatitis C and its effect on cellular immune function. Methods A total of 92 patients with chronic hepatitis C were enrolled in our hospital from June 2013 to October 2016. They were randomly divided into study group and control group by single and double numbers（ admission order）,with 46 cases in each group. The control group was treated with recombinant human interferon alpha-2b on the basis of conventional treatment. The study group was treated with pegylated interferon alpha-2a on the basis of conventional treatment. Results After treatment,the rates of RVR,EVR,ETVR and SVR in the study group（ 52. 17%,71. 74%,76. 09%and 54. 35%,respectively） were significantly higher than those in the control group（ 34. 78%,50%,58. 70%,39. 13%,respectively）,The difference was statistically significant（ P 〈0. 05）. There were no significant difference in the cellular immune function index between the two groups before treatment; After treatment,the CD3＋,CD4＋,CD4＋/CD8＋and other immune function indexes of the study group were significantly higher than those before treatment,while the results of CD8＋were significantly lower than before treatment（ P 〈0. 05）; There was no significant difference in the cellular immune function in the control group compared with before,and the difference of the cellular immune function between the 2 groups after treatment was statistically significant（ P 〈0. 05）. Conclusion Pegylated interferon（ IFN） on the basis of routine treatment can improve the virologic response and cellular immune function in patients with chronic hepatitis C.